Stock Markets

Daily coverage of equity markets, sectors, and major indices.

In-depth reporting on U.S. and global stock markets, including index performance, sector rotation, earnings reactions, volatility trends, and notable single-stock moves. Designed to help traders and investors understand what is driving price action across equities.

Articles

3,885 total articles

FDA Agrees to Review Moderna’s Revised Influenza Vaccine Application

FDA Agrees to Review Moderna’s Revised Influenza Vaccine Application

Moderna announced the U.S. Food and Drug Administration will review a revised application for its seasonal influenza vaccine after the agency rejected the company's initial submission a week earlier. The revised filing requests full approval for adults 50-64 and accelerated approval for those 65 and older, and includes a commitment to a post-market…

Morgan Stanley Flags Rising Intensity in MENA Dark-Store Grocery Race, Spotlights Careem and Talabat

Morgan Stanley Flags Rising Intensity in MENA Dark-Store Grocery Race, Spotlights Careem and Talabat

Morgan Stanley's field trip in Riyadh underscores that competition among dark-store grocery delivery operators in the MENA region is escalating. The bank identified Careem and Talabat as standout public-market stories, noting a larger total addressable market for grocery than for food delivery, but with thinner margins per order. Both companies are…

Kraft Heinz Appoints Nicolas Amaya to Lead North American Operations

Kraft Heinz Appoints Nicolas Amaya to Lead North American Operations

Kraft Heinz has named Nicolas Amaya as president of its North America business, replacing Pedro Navio effective February 23. The move comes a week after the packaged food maker paused plans to split the company and announced fresh investments to shore up its U.S. operations, which have been facing persistent demand weakness. New CEO Steve Cahillane…

Tempus AI Shares Climb After Rollout of HRD-RNA Cancer Detection Tool

Tempus AI Shares Climb After Rollout of HRD-RNA Cancer Detection Tool

Tempus AI, Inc. (NASDAQ:TEM) saw its stock rise 3.5% Wednesday following the announcement of HRD-RNA, a 1,660-gene logistic regression algorithm that evaluates Homologous Recombination Deficiency via tumor gene expression rather than DNA scarring. The algorithm is available for research use now, with clinical availability expected later this year. …